Erratum: Patient-assessed short-term positive response to cardiac resynchronization therapy is an independent predictor of long-term mortality (EP Europace (2014) 16:11 (1603-1609) DOI: 10.1093/europace/euu058);Patient-assessed short-term positive response to cardiac resynchronization therapy is an independent predictor of long-term mortality

Europace

Volumn 16, Issue 11, 2014, Pages 1603-1609

  Reitan, Christian ^a   Bakos, Zoltan ^a   Platonov, Pyotr G ^a   Höijer, Carl Johan ^a   Brandt, Johan ^a   Wang, Lingwei ^a   Borgquist, Rasmus ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

CRT; Heart failure; Long term follow up; Prognostic factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART ARREST; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PACEMAKER; PREDICTIVE VALUE; PROGNOSIS; QRS COMPLEX; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT RESPONSE; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; CONVALESCENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SELF EVALUATION; SELF REPORT; SEVERITY OF ILLNESS INDEX; SWEDEN; TERTIARY CARE CENTER; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIAC RESYNCHRONIZATION THERAPY; CHI-SQUARE DISTRIBUTION; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SELF REPORT; SELF-ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SWEDEN; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84912048735     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euy104     Document Type: Erratum

References (22)

1. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-1853.
2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure.NEngl J Med 2005;352:1539-49.
3. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
4. St John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association cla ss I/II heart failure. Circulation 2009; 120:1858-65.
5. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP et al. Cardiac-resynchronization therapy for the prevention of hear t-failure events. N Engl J Med 2009;361:1329-38.
6. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-95.
7. Daubert C, Gold MR, AbrahamWT, Ghio S, Hassager C, Goode Get al. Prevention of disease progression by cardiac resynchronization therapy in patients wit h asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009;54:1837 -46.
8. Di Biase L, Gasparini M, Lunati M, Santini M, Landolina M, BorianiGet al. Antiarrhythmic effect of reverse ventricular remodeling induced by cardiac resynchronization therapy: the InSync ICD (Implantable C ardioverter-Defibrillator) Italian Registry. J Am Coll Cardiol 2008;52:1442-9.
9. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA et al. 2013 ESC gui delines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15:1070-118.
10. Cleland JG, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L et al. Longtermmortalitywith cardiac resynchronization therapy in the cardiac resynch ronizationheart failure (CARE-HF) trial. Eur J Heart Fail 2012;14:628-34.
11. Bai R, Di Biase L, Elayi C, Ching CK, Barrett C, PhilippsKet al. Mortality of heart failure patients after cardi ac resynchronization therapy: identification of predictors. J Cardiovasc Electrophysiol 2008;19:1259-65.
12. Morani G, Gasparini M, Zanon F, Casali E, Spotti A, Reggiani A et al. Card iac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry. Eur opace 2013;15:1273-9.
13. MullensW,Grimm RA, VergaT, DresingT, Starling RC, Wilkoff BL et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease manag ement program. J Am Coll Cardiol 2009;53:765-73.
14. van Gelder BM, Bracke FA, Meijer A, Lakerveld LJ, Pijls NH. Effect of optimizing the VV interval on left ventricular contractility in card iac resynchronization therapy.AmJ Cardiol 2004;93:1500-3.
15. Nayar V, Khan FZ, Pugh PJ. Optimizing atrioventricular and interventricular intervals following cardiac resynchronization therapy. Expert Rev Cardiovasc Ther 2011;9: 185-97.
16. Vidal B, Sitges M, Marigliano A, DelgadoV, Diaz-Infante E, AzquetaMet al. Optimizing the programation of cardiac resynchronization therapy devices in patients with heart failure and left bundle branch block. Am J Cardiol 2007;100:1002-6.
17. Cleland JG, Tageldien A, Buga L, Wong K, Gorcsan J 3rd. Should we be trying to define responders to cardiac resynchronization therapy? JACC Cardiovasc Imaging 2010;3:541-9.
18. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001;7:176-82.
19. Zabarovska ja S, Gadler F, Braunschweig F, Stahlberg M, Hornsten J, Linde C et al. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace 2012;14:1148-55.
20. Arshad A,Moss AJ,Foster E,Padeletti L,Barsheshet A,Goldenberg I,et al. Cardiac resynchronization therapy is more effective inwomenthan in men: theMADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial w ith Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011, 57, 813-20.
21. Yarnoz MJ, Curtis AB. Sex-based differences in cardiac resynchronization therapy and implantable cardioverter defibrill ator therapies: effectiveness and use. Cardiol Rev 2006;14:292-8.
22. Kronborg MB, Mortensen PT, Kirkfeldt RE, Nielsen JC. Very long term follow-up of cardiac resynchronization therapy: clinical outcomeand predictors of mortality. Eur J Heart Fail 2008;10:796-801.